{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:01:57Z","timestamp":1790074917628,"version":"4.0.1"},"reference-count":36,"publisher":"Bioscientifica","issue":"2","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metastatic lesions occur in up to 36% of patients with pheochromocytoma. Currently there is no way to reliably detect or predict which patients are at risk for metastatic pheochromocytoma. Thus, the discovery of biomarkers that could distinguish patients with benign disease from those with metastatic disease would be of great clinical value. Using surface-enhanced laser desorption ionization protein chips combined with high-resolution mass spectrometry, we tested the hypothesis that pheochromocytoma pathologic states can be reflected as biomarker information within the low molecular weight (LMW) region of the serum proteome. LMW protein profiles were generated from the serum of 67 pheochromocytoma patients from four institutions and analyzed by two different bioinformatics approaches employing pattern recognition algorithms to determine if the LMW component of the circulatory proteome contains potentially useful discriminatory information. Both approaches were able to identify combinations of LMW molecules which could distinguish all metastatic from all benign pheochromocytomas in a separate blinded validation set.<\/jats:p>\n                  <jats:p>In conclusion, for this study set low molecular mass biomarker information correlated with pheochromocytoma pathologic state using blinded validation. If confirmed in larger validation studies, efforts to identify the underlying diagnostic molecules by sequencing would be warranted. In the future, measurement of these biomarkers could be potentially used to improve the ability to identify patients with metastatic disease.<\/jats:p>","DOI":"10.1677\/erc.1.00913","type":"journal-article","created":{"date-parts":[[2005,6,9]],"date-time":"2005-06-09T13:38:50Z","timestamp":1118324330000},"page":"263-272","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":43,"title":["Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma"],"prefix":"10.1530","volume":"12","author":[{"given":"F M","family":"Brouwers","sequence":"first","affiliation":[{"name":"1Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"E F","family":"Petricoin","sequence":"additional","affiliation":[{"name":"2NCI\/FDA Clinical Proteomics Program, Office of Cell and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Ksinantova","sequence":"additional","affiliation":[{"name":"3Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovak Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Breza","sequence":"additional","affiliation":[{"name":"4Department of Urology, Komensky Faculty of Medicine, Bratislava, Slovak Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Rajapakse","sequence":"additional","affiliation":[{"name":"5NCI\/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ross","sequence":"additional","affiliation":[{"name":"5NCI\/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Johann","sequence":"additional","affiliation":[{"name":"5NCI\/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Mannelli","sequence":"additional","affiliation":[{"name":"6Department of Clinical Physiopathology, Endocrine Unit, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B L","family":"Shulkin","sequence":"additional","affiliation":[{"name":"7Department of Radiological Sciences, St Jude Children\u2019s Research Hospital, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Kvetnansky","sequence":"additional","affiliation":[{"name":"3Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovak Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Eisenhofer","sequence":"additional","affiliation":[{"name":"8Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Walther","sequence":"additional","affiliation":[{"name":"9Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B A","family":"Hitt","sequence":"additional","affiliation":[{"name":"10Correlogic Systems Inc., Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T P","family":"Conrads","sequence":"additional","affiliation":[{"name":"11National Cancer Institute Biomedical Proteomics Program, Analytical Chemistry Laboratory, Mass Spectrometry Center, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T D","family":"Veenstra","sequence":"additional","affiliation":[{"name":"11National Cancer Institute Biomedical Proteomics Program, Analytical Chemistry Laboratory, Mass Spectrometry Center, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D P","family":"Mannion","sequence":"additional","affiliation":[{"name":"12Predictive Diagnostics Inc., Vacaville, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Wall","sequence":"additional","affiliation":[{"name":"12Predictive Diagnostics Inc., Vacaville, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G M","family":"Wolfe","sequence":"additional","affiliation":[{"name":"12Predictive Diagnostics Inc., Vacaville, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V A","family":"Fusaro","sequence":"additional","affiliation":[{"name":"5NCI\/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L A","family":"Liotta","sequence":"additional","affiliation":[{"name":"5NCI\/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Pacak","sequence":"additional","affiliation":[{"name":"1Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2026070905552089400_ADAM-ETAL-2002","unstructured":"Adam\n            BL\n          , Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z et al.2002 Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Research623609\u20133614."},{"key":"2026070905552089400_AEBERSOLD-AND-MANN-2003","unstructured":"Aebersold\n            R\n           & Mann M 2003 Mass spectrometry-based proteomics. Nature422198\u2013207."},{"key":"2026070905552089400_BROWN-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Brown\n            HM\n          , Komorowski RA, Wilson SD, Demeure MJ & Zhu YR 1999 Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: a positive correlation between MIB-1 staining and malignant tumor behavior. Cancer861583\u20131589.","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1583::AID-CNCR28>3.0.CO;2-#"},{"key":"2026070905552089400_CLARKE-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Clarke\n            W\n          , Silverman BC, Zhang Z, Chan DW, Klein AS & Molmenti EP 2003 Characterization of renal allograft rejection by urinary proteomic analysis. Annals of Surgery237660\u2013664.","DOI":"10.1097\/01.SLA.0000064293.57770.42"},{"key":"2026070905552089400_CONRADS-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Conrads\n            TP\n          , Fusaro VA, Ross S, Johann D, Rajapakse V, Hitt BA, Steinberg SM, Kohn EC, Fishman DA, Whitely G et al.2004 High-resolution serum proteomic features for ovarian cancer detection. Endocrine-Related Cancer11163\u2013178.","DOI":"10.1677\/erc.0.0110163"},{"key":"2026070905552089400_DANNENBERG-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Dannenberg\n            H\n          , Speel EJ, Zhao J, Saremaslani P, van Der Harst E, Roth J, Heitz PU, Bonjer HJ, Dinjens WN, Mooi WJ et al.2000 Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. American Journal of Pathology157353\u2013359.","DOI":"10.1016\/S0002-9440(10)64547-6"},{"key":"2026070905552089400_EDSTROM-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Edstrom\n            E\n          , Mahlamaki E, Nord B, Kjellman M, Karhu R, Hoog A, Goncharov N, Teh BT, Backdahl M & Larsson C 2000 Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. American Journal of Pathology156651\u2013659.","DOI":"10.1016\/S0002-9440(10)64769-4"},{"key":"2026070905552089400_ETZIONI-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Etzioni\n            R\n          , Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G & Hartwell L 2003 The case for early detection. Nature Reviews Cancer3243\u2013252.","DOI":"10.1038\/nrc1041"},{"key":"2026070905552089400_GOLDSTEIN-ETAL-1986","doi-asserted-by":"crossref","unstructured":"Goldstein\n            DS\n          , Stull R, Eisenhofer G, Sisson JC, Weder A, Averbuch SD & Keiser HR 1986 Plasma 3,4-dihydroxyphenylalanine (dopa) and catecholamines in neuroblastoma or pheochromocytoma. Annals of Internal Medicine105887\u2013888.","DOI":"10.7326\/0003-4819-105-6-887"},{"key":"2026070905552089400_GOLDSTEIN-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Goldstein\n            RE\n          , O\u2019Neill JA Jr, Holcomb GW 3rd, Morgan WM 3rd, Neblett WW 3rd, Oates JA, Brown N, Nadeau J, Smith B, Page DL et al.1999 Clinical experience over 48 years with pheochromocytoma. Annals of Surgery229755\u2013764.","DOI":"10.1097\/00000658-199906000-00001"},{"key":"2026070905552089400_GRIZZLE-AND-MELETH-2004","doi-asserted-by":"crossref","unstructured":"Grizzle\n            WE\n           & Meleth S 2004 Clarification in the point\/ counterpoint discussion related to surface-enhanced laser desorption\/ionization time-of-flight mass spectrometric identification of patients with adenocarcinomas of the prostate. Clinical Chemistry501475\u20131477.","DOI":"10.1373\/clinchem.2004.033456"},{"key":"2026070905552089400_HINGORANI-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Hingorani\n            SR\n          , Petricoin III EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA et al.2003 Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell4437\u2013450.","DOI":"10.1016\/S1535-6108(03)00309-X"},{"key":"2026070905552089400_JOHN-ETAL-1999","doi-asserted-by":"crossref","unstructured":"John\n            H\n          , Ziegler WH, Hauri D & Jaeger P 1999 Pheochromocytomas: can malignant potential be predicted? Urology53679\u2013683.","DOI":"10.1016\/S0090-4295(98)00612-8"},{"key":"2026070905552089400_KEBEBEW-AND-DUH-1998","doi-asserted-by":"crossref","unstructured":"Kebebew\n            E\n           & Duh QY 1998 Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-up. Surgical and Oncology Clinics of North America7765\u2013789.","DOI":"10.1016\/S1055-3207(18)30244-8"},{"key":"2026070905552089400_DE-KRIJGER-ETAL-1999","doi-asserted-by":"crossref","unstructured":"de Krijger\n            RR\n          , van der Harst E, van der Ham F, Stijnen T, Dinjens WN, Koper JW, Bruining HA, Lamberts SW & Bosman FT 1999 Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. Journal of Pathology18851\u201355.","DOI":"10.1002\/(SICI)1096-9896(199905)188:1<51::AID-PATH310>3.0.CO;2-R"},{"key":"2026070905552089400_LE-NAOUR-ETAL-2001","unstructured":"Le Naour\n            F\n          , Misek DE, Krause MC, Deneux L, Giordano TJ, Scholl S & Hanash SM 2001 Proteomics-based identification of RS\/DJ-1 as a novel circulating tumor antigen in breast cancer. Clinical Cancer Research73328\u20133335."},{"key":"2026070905552089400_LENDERS-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Lenders\n            JW\n          , Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS & Eisenhofer G 2002 Biochemical diagnosis of pheochromocytoma: which test is best? Journal of the American Medical Association2871427\u20131434.","DOI":"10.1001\/jama.287.11.1427"},{"key":"2026070905552089400_LI-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Li\n            J\n          , Zhang Z, Rosenzweig J, Wang YY & Chan DW 2002 Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clinical Chemistry481296\u20131304.","DOI":"10.1093\/clinchem\/48.8.1296"},{"key":"2026070905552089400_LINNOILA-ETAL-1990","unstructured":"Linnoila\n            RI\n          , Keiser HR, Steinberg SM & Lack EE 1990 Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Human Pathology211168\u20131180."},{"key":"2026070905552089400_LIOTTA-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Liotta\n            LA\n          , Ferrari M & Petricoin E 2003 Clinical proteomics: written in blood. Nature425905.","DOI":"10.1038\/425905a"},{"key":"2026070905552089400_MEHTA-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Mehta\n            AI\n          , Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EF 3rd & Liotta LA 2003 Biomarker amplification by serum carrier protein binding. Disease Markers191\u201310.","DOI":"10.1155\/2003\/104879"},{"key":"2026070905552089400_ORIORDAIN-ETAL-1996","unstructured":"O\u2019Riordain\n            DS\n          , Young WF Jr, Grant CS, Carney JA & van Heerden JA 1996 Clinical spectrum and outcome of functional extraadrenal paraganglioma. World Journal of Surgery20916\u2013921."},{"key":"2026070905552089400_ORLANDO-AND-GELMINI-2001","doi-asserted-by":"crossref","unstructured":"Orlando\n            C\n           & Gelmini S 2001 Telomerase in endocrine and endocrine-dependent tumors. Journal of Steroid Biochemistry and Molecular Biology78201\u2013214.","DOI":"10.1016\/S0960-0760(01)00101-7"},{"key":"2026070905552089400_ORNSTEIN-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Ornstein\n            DK\n          , Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, Veenstra TD, Liotta LA & Petricoin EF 3rd 2004 Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng\/ml. Journal of Urology1721302\u20131305.","DOI":"10.1097\/01.ju.0000139572.88463.39"},{"key":"2026070905552089400_PACAK-ETAL-2001A","doi-asserted-by":"crossref","unstructured":"Pacak\n            K\n          , Linehan WM, Eisenhofer G, Walther MM & Goldstein DS 2001a Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Annals of Internal Medicine134315\u2013329.","DOI":"10.7326\/0003-4819-134-4-200102200-00016"},{"key":"2026070905552089400_PACAK-ETAL-2001B","doi-asserted-by":"crossref","unstructured":"Pacak\n            K\n          , Chrousos GP, Koch CA, Lenders JW & Eisenhofer G 2001b Pheochromocytoma: progress in diagnosis, therapy, and genetics. In Adrenal Disorders, edn 1, pp 479\u2013523. Eds A Margioris & GP Chrousos. Totowa: Humana Press.","DOI":"10.1007\/978-1-59259-101-5_28"},{"key":"2026070905552089400_PETRICOIN-ETAL-2002A","doi-asserted-by":"crossref","unstructured":"Petricoin\n            EF\n          , Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC et al.2002a Use of proteomic patterns in serum to identify ovarian cancer. Lancet359572\u2013577.","DOI":"10.1016\/S0140-6736(02)07746-2"},{"key":"2026070905552089400_PETRICOIN-ETAL-2002B","unstructured":"Petricoin\n            EF\n           3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K et al.2002b Serum proteomic patterns for detection of prostate cancer. Journal of the National Cancer Institute941576\u20131578."},{"key":"2026070905552089400_QU-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Qu\n            Y\n          , Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ & Wright GL Jr 2002 Boosted decision tree analysis of surface-enhanced laser desorption\/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clinical Chemistry481835\u20131843.","DOI":"10.1093\/clinchem\/48.10.1835"},{"key":"2026070905552089400_RAO-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Rao\n            F\n          , Keiser HR & O\u2019Connor DT 2002 Malignant and benign pheochromocytoma: chromaffin granule transmitters and the response to medical and surgical treatment. Annals of the New York Academy of Sciences971530\u2013532.","DOI":"10.1111\/j.1749-6632.2002.tb04519.x"},{"key":"2026070905552089400_RUI-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Rui\n            Z\n          , Jian-Guo J, Yuan-Peng T, Hai P & Bing-Gen R 2003 Use of serological proteomic methods to find biomarkers associated with breast cancer. Proteomics3433\u2013439.","DOI":"10.1002\/pmic.200390058"},{"key":"2026070905552089400_SINZ-ETAL-2002","unstructured":"Sinz\n            A\n          , Bantscheff M, Mikkat S, Ringel B, Drynda S, Kekow J, Thiesen HJ & Glocker MO 2002 Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis. Electrophoresis233445\u20133456."},{"key":"2026070905552089400_TANAKA-ETAL-1993","doi-asserted-by":"crossref","unstructured":"Tanaka\n            S\n          , Ito T, Tomoda J, Higashi T, Yamada G & Tsuji T 1993 Malignant pheochromocytoma with hepatic metastasis diagnosed 20 years after resection of the primary adrenal lesion. Internal Medicine32789\u2013794.","DOI":"10.2169\/internalmedicine.32.789"},{"key":"2026070905552089400_VYTVYTSKA-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Vytvytska\n            O\n          , Nagy E, Bluggel M, Meyer HE, Kurzbauer R, Huber LA & Klade CS 2002 Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics2580\u2013590.","DOI":"10.1002\/1615-9861(200205)2:5<580::AID-PROT580>3.0.CO;2-G"},{"key":"2026070905552089400_WADSWORTH-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Wadsworth\n            JT\n          , Somers KD, Cazares LH, Malik G, Adam BL, Stack BC Jr, Wright GL Jr & Semmes OJ 2004 Serum protein profiles to identify head and neck cancer. Clinical Cancer Research101625\u20131632.","DOI":"10.1158\/1078-0432.CCR-0297-3"},{"key":"2026070905552089400_WULFKUHLE-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Wulfkuhle\n            JD\n          , Liotta LA & Petricoin EF 2003 Proteomic applications for the early detection of cancer. Nature Reviews Cancer3267\u2013275.","DOI":"10.1038\/nrc1043"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/12\/2\/263\/149654\/0120263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/12\/2\/263\/149654\/0120263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:55:30Z","timestamp":1783590930000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/12\/2\/263\/26646\/Low-molecular-weight-proteomic-information"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,1]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6,1]]}},"URL":"https:\/\/doi.org\/10.1677\/erc.1.00913","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6,1]]}}}